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Osteoclastfor normal skeletal development and maintenance of the adult skeleton, but the
mechanisms which control supply of thyroid hormone to bone cells are poorly understood. Thyroid
hormones enter target cells via monocarboxylate transporter-8 (MCT8), which provides a functional link
between thyroid hormone uptake and metabolism in the regulation of T3-action but has not been
investigated in bone. Most circulating active thyroid hormone (T3) is derived from outer ring deiodination of
thyroxine (T4) mediated by the type 1 deiodinase enzyme (D1). The D2 isozyme regulates intra-cellular T3
supply and determines saturation of the nuclear T3-receptor (TR), whereas a third enzyme (D3) inactivates
T4 and T3 to prevent hormone availability and reduce TR-saturation. The aim of this study was to determine
whether MCT8 is expressed in the skeleton and whether chondrocytes, osteoblasts and osteoclasts express
functional deiodinases. Gene expressionwas analyzed by RT-PCR and D1, D2 and D3 function by sensitive and
highly speciﬁc determination of enzyme activities. MCT8 mRNA was expressed in chondrocytes, osteoblasts
and osteoclasts at all stages of cell differentiation. D1 activity was undetectable in all cell types, D2 activity
was only present in mature osteoblasts whereas D3 activity was evident throughout chondrocyte, osteoblast
and osteoclast differentiation in primary cell cultures. These data suggest that T3 availability especially
during skeletal development may be limited by D3-mediated catabolism rather than by MCT8 mediated
cellular uptake or D2-dependent T3 production.
© 2008 Elsevier Inc.Open access under CC BY license.Introduction
Bone development occurs via endochondral ossiﬁcation, in which
proliferation, differentiation and apoptosis of growth plate chondro-
cytes is co-ordinated to produce a cartilage scaffold that is mineralized
during bone formation [39]. Hypothyroidism in children results in
delayed bone age and growth arrest [58], and T4-treatment induces
rapid “catch-up” growth [60]. Juvenile thyrotoxicosis, by contrast,
advances bone age and accelerates growth but results in short stature
due to premature closure of the growth plates [68]. In adults,
hypothyroidism reduces bone turnover, whereas thyroid hormone
excess increases bone formation and resorption [52]. The increased
and unbalanced bone turnover in thyrotoxicosis generates a net
increase in osteoclast activity leading to accelerated bone loss,
osteoporosis and increased fracture susceptibility [9,53,75]. Thus,up, 5th Floor Clinical Research
ospital, Du Cane Road, London,
R. Williams).
 license.euthyroidism is critical for skeletal development and maintenance of
adult bone [7,32].
The iodothyronine deiodinases are selenoenzymes that activate or
inactivate thyroid hormones. The type 2 deiodinase (D2) catalyzes
removal of an outer ring iodine atom from the prohormone thyroxine
(T4) with an apparent Michaelis constant (Km) of 10−9 M to generate
the active product 3,5,3'-triiodothyronine (T3). By contrast, the D3
isozyme inactivates T3, or prevents T4 from being activated, by
catalyzing the removal of an inner ring iodine with a Km of 10−9 M to
generate 3,3'-diiodothyronine (T2) or 3,3',5'-triiodothyronine (reverse
T3, rT3) respectively. The D1 enzyme however is inefﬁcient, with a Km
of 10−6–10−7 M, and catalyzes removal of inner or outer ring iodine
atoms in equimolar proportions to generate T3, rT3 or T2 depending
on the substrate. Most circulating T3 is derived from T4 by the actions
of D1 in liver and kidney, although D2 in skeletal muscle also
contributes [12,14,47]. Nevertheless, the primary action of D2 is to
determine the intra-cellular concentration of T3 and level of
saturation of the nuclear T3-receptor (TR). Its lower Km enables
efﬁcient local generation of T3 at times of T4 deprivation and D2 is
thought to protect vital structures from periods of hypothyroidism.
127A.J. Williams et al. / Bone 43 (2008) 126–134Thyroid hormones enter target cells via monocarboxylate transporter-
8 (MCT8) [28] and other transporter proteins [36]. MCT8 is expressed
in many T3-responsive tissues, but has not been investigated in bone
[36]. T4 treatment of cells co-expressing MCT8 and D2 results in
increased T3 production and hormone responsiveness [28], demon-
strating a functional link between thyroid hormone uptake and
metabolism in the regulation of T3-action.
The inactivating D3 isozyme prevents thyroid hormone access to
speciﬁc tissues at critical times and reduces TR-saturation [12,14]. D3 is
expressed in fetal tissues and placenta where it prevents maternal
thyroid hormone access to the developing fetus [77]. At this time un-
occupiedTRs are critical factors that generallymaintain cell proliferation
and prevent differentiation [19,27]. The sharp rise in T3 availability at
birth in mammals is analogous to the T3-dependent metamorphosis
climax in amphibians [35] and a similar period at hatching in birds [73],
and depends on tightly regulated temporo-spatial expression of D2 and
D3 [8]. Increased pituitary D2 expression correlates with maturation of
the hypothalamic–pituitary–thyroid (HPT) axis whilst its expression in
T3-target tissues, concomitant with reduced expression of D3, results
in conversion of unoccupied TRs into occupied TRs and the initia-
tion of cell differentiation [18,27,35,46,54,62]. Thus, the TR acts as a
deiodinase-dependent developmental switch that regulatesmaturation
of T3-dependent tissues. Accordingly, a role for D2 to regulate os-
siﬁcation in the developing embryo has emerged [23]. In this case
Hedgehog signalling in the perichondrium activates the ubiquitin ligase
subunitWSB-1 leading to degradation of D2 protein in the growth plate
and increased PTHrP signalling,which regulates thepaceof chondrocyte
differentiation during early skeletogenesis [23].
Current information regarding expression of the deiodinases in
bone is inconsistent. There are no previous studies investigatingMCT8
or D3 in skeletal cells and analysis of D1 is incomplete. A single study
in chondrogenic ATDC5 embryonal carcinoma cells was discordant,
demonstrating detectable D1 mRNA expression and an absence of D1
enzyme activity [50], but D1 has not been investigated in primary
chondrocytes. Several biochemical studies have also failed to identify
6-n-propylthiouracil (PTU) sensitive D1 activity in osteoblastic cells
[24,30,42], suggesting D1 may be absent from osteoblasts. D1 ex-
pression has not been studied in osteoclasts. Expression of D2 has also
never been investigated in osteoclasts but previous studies in
chondrocytes and osteoblasts are contradictory. D2 mRNA has been
demonstrated in chicken growth plate chondrocytes [69] and in
ATDC5 cells, mouse calvarial osteoblasts and bone marrow stromal
ST2 cells [50]. Some studies comparing relative potencies of T3 and T4
and using the D1 inhibitor PTU have suggested indirectly that D2
activity may also be present in primary chondrocytes, ATDC5 cells and
a whole organ bone resorption assay [1,17,50], whereas other studies
of growth plate organ cultures and primary chondrocytes reached the
opposite conclusion [2,16,76]. Biochemical studies using radiolabeled
rT3 substrate identiﬁed a D2-like activity in ATDC5 cell extracts and
growth plate organ culture extracts by measurement of 125I− release
following assay incubation periods of 6–12 h [50]. In these experi-
ments characterization of D2-like activity was incomplete and the 5'-
deiodination detected has been proposed to be non-speciﬁc [30].
There are further inconsistencies regarding D2 expression in osteo-
blastic cells. D2-like 5'-deiodination activity was undetectable in
UMR106 osteosarcoma cells [42] and human fetal osteoblasts [24],
whereas Gouveia et al. [30] reported low levels of well-characterized
speciﬁc D2 activity in osteoblastic cells as well as substantial non-
speciﬁc 5'-deiodination of undeﬁned origin. In addition to these stud-
ies, Morimura et al. [51] reported D2-like activity in SaOS-2 osteo-
sarcoma cells and human NHOst cells. However, similar to studies in
ATDC5 cells [50], detection of D2-like activity was based solely on the
release of 125I− following incubation of cell extracts with radiolabelled
T4 or rT3 [51]. As release of 125I− may result from non-speciﬁc
degradation of substrate [30], the speciﬁcity of D2-like activity iden-
tiﬁed in osteoblastic cells [51] requires clariﬁcation.The aim of this study was to determine whether MCT8 and D3 are
expressed in bone and clarify expression of D1 and D2 in skeletal cells.
We studied chondrocytes, osteoblasts and osteoclasts comprehen-
sively and determined deiodinase activities using highly speciﬁc and
sensitive assays that determined production of iodothyronine meta-
bolites directly by high performance liquid chromatography (HPLC).
Materials and methods
Chondrocytes — ATDC5 cells and primary growth plate chondrocytes
ATDC5 cells were maintained in DMEM/Ham's F12 (Life Technologies, Paisley, UK)
containing 5% fetal calf serum (FCS), 10 μg/ml transferrin (Sigma, Poole, UK) and sodium
selenite 100 nM [3,70]. Cells were plated (12,500 cells/cm2) in medium containing 5%
FCS stripped of thyroid hormones (SFCS) [64]. On day 1, medium was replaced with
medium containing 5% SFCS and 10 μg/ml bovine insulin±T3 (10 nM) or T4 (10 or
100 nM) in the absence or presence of PTU (0.1 or 1 mM). Growth was measured at days
3, 7 and 10 using 0.4% sulforhodamine-B (SRB; Sigma) as an indicator of cell number
[61,70]. We previously reported that alkaline phosphatase (ALP) expression is
accelerated by T3 in ATDC5 cells as they undergo differentiation [70]. Cells were
stained for ALP using 5-bromo-4-chloro-3indolylphosphate/nitroblue tetrazolium as
substrate (BCIP/NBT; Sigma). To investigate deiodinase enzyme activities, cells were
treated with dexamethasone 1 µM, T3 100 nM, T4 100 nM or dibutyryl cAMP 1 mM for
24 h, or phorbol-12-myristate-13-acetate (TPA) 0.1 µM for 6 h prior to harvest. Proximal
tibia growth plate chondrocytes were isolated from 3, 6 and 12 week male rats as
described [61]. Cells were washed three times in serum-free medium (SFM) and diluted
in DMEM/F12 supplemented with 10% FCS (Harlan SeraLab, Loughborough, UK), 10 μg/
ml transferrin (Sigma) and sodium selenite 100 nM, before seeding at 7500–12,500
cells/cm2 [61]. Primary cells were cultured until 75% conﬂuent (4–6 days), and treated
with dexamethasone 1 µM, T3 100 nM, T4 100 nM or dibutyryl cAMP 1 mM for 24 h, or
TPA 0.1 µM for 6 h.
Osteoblasts — MC3T3-E1 cells, rat and mouse neonatal calvarial osteoblasts and SV-HFO
cells
Neonatal calvarial osteoblasts were isolated by sequential collagenase digestion
[10,71]. Primary osteoblasts and mouse osteoblastic MC3T3-E1 cells (ATCC CRL-2593)
were seeded at 15,000 cells/cm2 and maintained for up to 28 days in α-MEM plus 10%
SFCS, 50 μg/ml ascorbic acid, β-glycerophosphate 2 mM, sodium selenite 100 nM,
penicillin/streptomycin 18 U/ml and amphotericin B 1.35 μg/ml at 37 °C and 5% CO2.
Calvarial osteoblasts and MC3T3-E1 cells were treated with T3 100 nM, T4 100 nM or
dexamethasone 1 µM throughout the period of culture. SV-HFO human fetal osteoblasts
[20] were seeded at 10,000 cells/cm2 and maintained in MEM (Gibco BRL, Paisley, UK)
plus 20 mM HEPES, 100 IU/ml penicillin, 100 µg/ml streptomycin, 1.8 mM CaCl2"2H2O,
100 nM sodium selenite and 2% SFCS at 37 °C and 5% CO2 [25]. SV-HFO cells were treated
with MEM alone or with medium supplemented with T3 100 nM or dexamethasone
1 µM for 1, 7, 14 or 21 days.
Osteoclasts — primary rat and mouse osteoclasts and RAW 264.7 cells
Bone marrow was obtained from tibias and femurs of 6–8 week old male rats or
mice and cultures established in α-MEM supplemented with 10% SFCS, 100 nM sodium
selenite, hM-CSF 25 ng/ml and RANKL 10 ng/ml at 37 °C in 5% CO2 [41]. The following
day non-adherent cells were removed, ﬁltered with a 70 μm strainer and plated at
150,000 cells/cm2 in α-MEM plus 10%, hM-CSF 25 ng/ml, 1% glutamine and penicillin/
streptomycin 18 U/ml in the absence or presence of RANKL 10 ng/ml. After 5 days, cells
were stained with tartrate-resistant acid phosphatase (TRAP) and examined for
formation of multinucleated osteoclasts, which occurred in all cultures in the presence
of RANKL. Murine RAW 264.7 monocytic cells (ATCC TIB-71) were cultured in DMEM
containing 10% SFCS and sodium selenite 100 nM in the absence or presence of RANKL
20 ng/ml (R&D Systems, Abingdon, UK) [43,74].
Measurement of deiodinase activities
Experiments to determine deiodinase activities in skeletal tissues and primary cells
required large numbers of animals to obtain sufﬁcient tissue sample for analysis, and
assays were optimized to ensure that deiodinase activities were measured reliably and
reproducibly. Enzyme activities were determined using highly speciﬁc and sensitive
assays that measured 125I− release as well as direct determination of iodothyronine
metabolite production by HPLC [29]. In some instances cells were treated with
dexamethasone, cAMP or TPA to induce deiodinase activities above basal levels in order
to facilitate detection of enzyme activity under optimal conditions and determine
whether the deiodinases are regulated by extra-cellular signals in skeletal cells [14].
Treatment of cells with dexamethasone [72] or cAMP [44] induces D2 whereas treat-
ment with TPA induces D3 [22], thereby resulting in favorable conditions for mea-
surement of the activities of these two enzymes [14]. cAMP also increases expression
and activity of D1, whereas dexamethasone inhibits D3 mRNA expression and may also
inhibit D1 activity [14]. In most cases results were obtained from duplicate or triplicate
wells in two independent experiments and the deiodinase activities represent the
Table 1
Deiodinase enzyme activities in growth plate tissue extracts and chondrocytes
ATDC5 2, 7, 14,
21 day extracts
and intact cells
n=4 in duplicate
Growth plate
tissue 3, 6,
12 week rat
extracts 6–12
rats/age/
experiment n=2
in duplicate
1° chondrocytes
3 week rat
extracts 12 rat s/
experiment n=2
in duplicate
1° chondrocytes
6, 12 week rat
extracts 6 rats/
age/experiment
n=2 in duplicate
D1 (fmol/
min/mg)
0 0 N/D N/D
D2 (fmol/
min/mg)
0 0 0 0
D3 (fmol/
min/mg)
Con 0 0 2.9 0
Dex 1 μM 0 0 1.2 0
T3 100 nM 0 0 0.6 0
T4 100 nM 0 0 1.9 0
cAMP
1 mM
0 0 4.6 0
TPA
0.1 μM
0 0 4.3 0
D1 enzyme activities were not determined in samples from primary chondrocytes
because of limiting amounts of cell extract. Positive control adult human liver extracts
deiodinated 100% of substrate in each 120 min D1 assay; COS-1 cell extracts transfected
with human D2 possessed 12.06 fmol/min/mg D2 activity; ECC1 cell and human fetal
liver extracts possessed D3 activities of 9.83 and 208 fmol/min/mg, respectively.
Table 3
Deiodinase enzyme activities in osteoclasts
Primary rat monocyte −
RANKL extracts 3 rats
n=2 in triplicate
Primary rat osteoclast +
RANKL extracts 3 rats
n=2 in triplicate
RAW 264.7 3, 5, 7 day
extracts and intact cells
n=2 in triplicate
D1
(fmol/
min/mg)
0 0 0
D2
(fmol/
min/mg)
0 0 0
D3
(fmol/
min/mg)
1.13 1.0 0
Positive control adult human liver extracts deiodinated 100% of substrate in each
120min D1 assay; COS-1 cell extracts transfected with human D2 possessed 12.06 fmol/
min/mg D2 activity; ECC1 cell and human fetal liver extracts possessed D3 activities of
9.83 and 208 fmol/min/mg, respectively.
128 A.J. Williams et al. / Bone 43 (2008) 126–134mean value from the two experiments. In day 28mouse calvarial osteoblasts D2 activity
data were obtained from samples obtained from 3 independent experiments that were
pooled and assayed in duplicate because concentrated protein is required for
determination of D2 activity to ensure enzyme stability is maximized. D3 activities
from these studies were determined in duplicate for each of the 3 independent
experiments. Details of the numbers of animals used for tissue and cell preparations,
the numbers of independent experiments performed and the numbers of replicate
wells assayed per experiment are provided in Tables 1–3.
Deiodinase activities in cell lysates
ATDC5, MC3T3-E1, SV-HFO and RAW 264.7 cells, and primary chondrocytes,
osteoblasts or osteoclasts were washed in ice-cold PBS, sonicated for 20 s in lysis buffer
(0.1 M Na+ phosphate pH7.2 [0.075 M Na2HPO4+0.028 M NaH2PO4], 2 mM EDTA, 1 mM
DTT) and stored at −80 °C prior to determination of D1, D2 and D3 enzyme activities.
Some proximal tibia growth plates were dissected, excised, minced and sonicated in
lysis buffer prior to storage at −80 °C. D1 assays were performed on undiluted lysates
(0.2–0.7 mg/ml) for 120–180 min in the presence of 100 nM rT3 (including 1×105 cpm
of [3',5'-125I]rT3 tracer) and DTT 10 mM at 37 °C, and the absence or presence of 0.1 mM
PTU. Adult human liver extracts were included as a positive control for D1 activity in all
assays [59]. Reactions were stopped by addition of 0.1 ml ice-cold 5% BSA. Protein-
bound [125I]iodothyronines were precipitated by addition of 0.5 ml 10% trichloroacetic
acid on ice. After centrifugation, supernatants were analyzed for 125I− production onTable 2
Deiodinase enzyme activities in osteoblasts
MC3T3 day 28
extracts n=2–3
in duplicate
Mouse calvarial day 28
extracts 6–8 mice n=3
in duplicate
Rat calvarial day 11
extracts 6–8 rats n=2
in duplicate
Rat calvar
extracts 6
in duplica
D1 (fmol/
min/mg)
0 0 0 0
D2 (fmol/
min/mg)
0 0.21 n=3 pooled
in duplicate
0 0
D3 (fmol/
min/mg)
Con 0 1.35±0.15 1.5 0.4
Dex 1 μM 0 N/D 1.9 1.8
T3 100 nM 0 N/D 2.0 2.7
T4 100 nM 0 N/D 1.4 3.4
Positive control adult human liver extracts deiodinated 100% of substrate in each 120 min D1
activity; ECC1 cell and human fetal liver extracts possessed D3 activities of 9.83 and 208 fmSephadex LH-20 minicolumns (bed volume, 0.25 ml), which were equilibrated and
eluted with 0.1 M HCl. D2 assays were performed on undiluted lysates (0.2–0.7 mg/ml)
for 120–180 min in the presence of 1 nM T4 (including 1×105 cpm of [3',5'-125I]T4
tracer) and DTT 10 mM at 37 °C, and the absence or presence of an enzyme saturating
concentration of T4 (100 nM or 500 nM). Extracts from COS-1 cells transfected with a
human D2 cDNA were included as a positive control in all assays [40]. Release of 125I−
was determined as described for D1 activity. D3 assays were performed on undiluted
lysates (0.2–0.7 mg/ml) for 120min in the presence of 1 nM T3 (including 2×105 cpm of
[3'-125I]T3 tracer) and DTT 10mM at 37 °C. Extracts fromhuman endometrial carcinoma
ECC1 cells treated with estradiol (10 nM) or human fetal liver were included as positive
controls for D3 activity in all assays [37,59]. Reactions were stopped by addition of
0.1 ml ice-cold methanol. After centrifugation, supernatants were mixed with an equal
volume of ammonium acetate (pH 4.0), and the mixtures from D1, D2 and D3 assays
were analyzed by HPLC as described [29].
Iodothyronine metabolism in intact cells
ATDC5, SV-HFO and RAW 264.7 cells were cultured with 1 nM (1×106 cpm) 125I-
labeled T4, T3 or rT3 in 0.5 ml medium plus 0.1% BSA for 24 h. After incubation, 100 μl
medium was added to 100 μl ice-cold methanol. After centrifugation, 100 μl of
supernatant was mixed with 100 μl ammonium acetate (pH 4.0) 0.02 M and 100 μl of
the mixture was applied to a 4.6×250 mm Symmetry C18 column connected to an
Alliance HPLC system (Waters, Etten-Leur, The Netherlands), as described [29].
Radioactivity in the eluate was monitored on line using a Radiomatic A-500 ﬂow
scintillation detector (Packard Instruments, Meriden, CT).
RNA extraction and RT-PCR
MCT8 and D1, D2 and D3 expression was determined by RT-PCR [3,61,70] using the
following primers: rat D1 (GenBank NM_021653): forward primer, nucleotides 68–87;
reverse, 305–286; rat D2 (NM_031720): forward, 308–327; reverse, 916–896; rat D3
(NM_017210): forward, 99–118; reverse, 447–428; rat glyceraldehyde-3-phosphate
dehydrogenase (GAPDH, NM_017008): forward, 597–616; reverse, 1048–1029; mouse
D1 (NM_007860): forward, 315–334; reverse, 648–629;mouseD2 (NM_010050): forward,ial day 18
–8 rats n=2
te
Rat calvarial day 20
extracts 6–8 rats n=2
in duplicate
Rat calvarial day 27
extracts 6–8 rats n=2
in duplicate
SV-HFO 1, 7, 14, 21 day
extracts and intact cells
n=2 in duplicate
0 0 0
0 0 0
2.5 3.1 0
6.0 4.3 0.5 d14
2.5 d21
2.5 3.5 0
2.8 3.5 0
assay; COS-1 cell extracts transfected with human D2 possessed 12.06 fmol/min/mg D2
ol/min/mg, respectively.
129A.J. Williams et al. / Bone 43 (2008) 126–134240–259; reverse, 829–810;mouseD3 (NM_172119): forward,160–177; reverse, 574–557;
mouse MCT8 (AF045692): forward, 552–571; reverse, 933–914; mouse runx-2
(NM_009820): forward, 703–723; reverse, 1084–1064; mouse twist-2 (NM_007855):
forward, 151–168; reverse, 698–680; mouse osteocalcin (L24429): forward, 21–40;
reverse, 449–429; mouse ALP (X13409): forward, 412–432; reverse, 785–765; mouse
collagen Ia1 (X15896): forward, 1247–1268; reverse, 1518–1498; mouse cathepsin K
(NM_007802): forward, 54–74; reverse, 663–639; mouse TRAP (NM_007388): forward,
123–145; reverse, 882–861; mouse calcitonin receptor (NM_007588): forward, 376–396;
reverse, 1108–1088; mouse GAPDH (NM_008084): forward, 566–585; reverse, 1017–998;
mouse 18 S rRNA (X00686) forward,1577–1596; reverse,1727–1708. PCRswereperformed
with a denaturation step at 94 °C for 3min followed by 30–35 cycles of 30 s at 94 °C, 30 s at
58–64 °C depending on the primer pair, and 30 s at 72 °C, followed by termination at 72 °C
for 5 min. PCR products were subcloned and sequenced.
Quantitative real-time PCR
cDNAwas prepared from ATDC5 cells and primary osteoblasts and osteoclasts [74].
Quantitative real-time PCR was performed using an ABI PRISM 7700 system (Applied
Biosystems, Nieuwerkerk aan den IJssel, The Netherlands). Reactions were performed in
25 µl Taqman universal PCR master mix (Applied Biosystems), containing 20 ng cDNA.Fig. 1. Deiodinase and MCT8 expression and effect of thyroid hormones on chondrogenesis
during ATDC5 cell differentiation (proliferating day 6, cartilage nodule formation day 12, pre-
28) [3,70]. Negative control (−RT) samples inwhich cDNA template was omitted and positive
proliferation of ATDC5 cells in response toT3 (10 nM) or T4 (10 nM and 100 nM) in the absenc
SEM, n=6, ⁎Pb0.05, ⁎⁎Pb0.01, ⁎⁎⁎Pb0.001 compared to control. Panel C shows chondroge
untreated ATDC5 cells and cells treated with T3 10 nM, T4 100 nM and T4 100 nM+PTU
representative of studies performed 3 times.Each reaction contained 200 nM D1 primers (5'-TTAGTTCCATAGCAGATTTTCTTGTCA-3'
and 5'-CTGATGTCCATGTTGTTCTTAAAAGC-3') and probe (5'-FAM-AGCCATCTGATG-
CATGTGCTTCTTCAATG-TAMRA-3'), 200 nM D2 primers (5'-CAAGTCCACTCGCGGAGAGT-3' and
5'-GACATGCACCACACTGGAATTG-3') and probe (5'-FAM-ACGCAGCGCAGTCCCTCTGAGG-TAMRA-3'), 200 nM
D3 primers (5'-TTCCAGAGCCAGCACATCCT-3' and 5'-ACGTCGCGCTGGTACTTAGTG-3')
and probe (5'-FAM-TGCACCTGACCACCGTTCATGGC-TAMRA-3') or 300 nM MCT8
primers (5'-CCATAACTCTGTCGGGATCCTC-3' and 5'-ACTCACAATGGGAGAACAGAA-
GAAG-3') and probe (5'-FAM-ATACCCATCGCGAGGGCTCCGA-TAMRA-3'). mRNA levels
were expressed relative to GAPDH. Pre-optimized control GAPDH primers and probe
were obtained from Applied Biosystems. PCR reactions were performed for an initial
cycle of 2 min at 50 °C and 10 min at 95 °C, followed by 30–35 cycles of 15 s at 95 °C and
1 min at 60 °C. The cycle at threshold (Ct) values represent the cycle numbers at which
probe-derived absorbance reached the calculated threshold value. Data are expressed
as 2−ΔCt"ΔCt⁎1000 (mRNA copies relative to expression of GAPDH) [45].
Statistics
Differences between normally distributed data sets were examined for statistical
signiﬁcance using two-tailed Student's t tests or by ANOVA followed by Tukey's post-
hoc test as appropriate. P values of b0.05 were considered signiﬁcant.in ATDC5 cells: Panel A shows expression of D1, D2, D3, MCT8 and 18 s ribosomal RNA
hypertrophic differentiation day 21, hypertrophic differentiation andmineralization day
control (+ve) samples (liver for D1, heart for D2, brain for D3) are shown. Panel B shows
e or presence of PTU (0.1mM and 1mM) after 3, 7 and 10 days. Data expressed asmean±
nesis assessed by alkaline phosphatase staining of cartilage nodules after 15 days in
0.1 mM. Images are from single wells of an experiment performed in duplicate and
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Chondrocytes express MCT8 mRNA
MCT8 facilitates entry of thyroid hormones into target cells and is a
rate-limiting determinant of intra-cellular thyroid hormone metabo-
lism [29]. MCT8 mRNA was expressed at all stages of chondrogenesis
in ATDC5 cells cultured over 28 days, whereas D1, D2 and D3 mRNAs
were undetectable at all time points (Fig. 1A). In RT-PCR experiments
using RNA from 3, 6 and 12 week old rat growth plates, D1 mRNAwas
also absent. Low levels of D2 and D3 mRNA expression were
detectable only following 40 PCR ampliﬁcation cycles (data not
shown). Thus, D1 was not expressed in chondrocytes, whilst D2 andFig. 2. Deiodinase and MCT8 expression in differentiating osteoblasts: Panel A, left graph sho
The graph on the right shows the effect of T3 (100 nM) on alkaline phosphatase activity in M
compared to control. RT-PCR gels on left show expression of D1, D2, D3, MCT8 and 18 s rib
osteoblasts day 14, terminal osteoblasts day 21, mineralization day 28) [10,15,71]. Negative
samples (liver for D1, heart for D2, brain for D3) are shown. Gels on right show expression of t
collagen Ia1 (Col1a) in mouse calvarial osteoblasts cultured for 28 days in the absence or pre
expression in differentiating human SV-HFO cells. ΔCT indicates cycle threshold detection le
n=3 each time point.D3 mRNAs were expressed at the limit of detection in growth plate
RNA.
Effects of T4 on chondrogenesis do not involve D1-mediated conversion
of T4 to T3
In view of previous studies showing discrepant responses of
chondrocytes to thyroid hormones [1,2,16,50,76] effects of T3 and T4
on ATDC5 cell proliferation were examined during the ﬁrst 10 days of
culture, and effects on ALP expression were determined at day 15
(Figs.1B and C). T3 (10 nM) inhibited cell proliferation, consistent with
previous studies [61,70], whereas T4 (10 nM) or the D1-speciﬁc
inhibitor PTU (0.1 mM and 1 mM) had no effect. T4 (100 nM) alsows the effect of T3 (100 nM) on proliferation of MC3T3-E1 cells between 7 and 21 days.
C3T3-E1 cells between 7 and 28 days. Data expressed as mean±SEM, n=3, ⁎⁎⁎Pb0.001
osomal RNA during mouse calvarial osteoblast differentiation (proliferating day 7, pre-
control (−RT) samples in which cDNA template was omitted and positive control (+ve)
he osteoblast markers Runx-2, Twist-2, osteocalcin (OC), alkaline phosphatase (ALP) and
sence of T3 (100 nM). Panel B shows real-time qRT-PCR analysis of D1, D2, D3 and MCT8
vel of MCT8 or deiodinase expression relative to GAPDH; data expressed as mean±SEM,
Fig. 3. Deiodinase and MCT8 expression in differentiating osteoclasts: Panel A shows
formation of resorption pit trails on dentine slices by differentiating osteoclasts cultured
with RANKL for 9 days and imaged by back-scattered electron scanning electron
microscopy (BSE-SEM) or by light microscopy following staining with toluidine blue [6].
Multinucleated osteoclasts were visualized following immunohistochemical staining
for TRAP [6], and differentiated cells expressed the calcitonin receptor (Ctr) and Trap
mRNAs. Panel B shows expression of D1, D2, D3, MCT8 and 18 s ribosomal RNA during
osteoclastogenesis in bonemarrow osteoclasts cultured in the presence of RANKL for 3–
9 days. Negative control (−RT) samples in which cDNA template was omitted and
positive control (+ve) samples (liver for D1, heart for D2, brain for D3) are shown.
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indicating that a 10-fold higher concentration of T4 than T3 was
necessary to inhibit cell growth and that D1-dependent conversion of
T4 to T3 was not required (Fig. 1B). T3 (10 nM) and T4 (100 nM) also
increased ALP expression and the effect of T4 was not inhibited by
PTU, further demonstrating that responses to T4 (100 nM) are
independent of D1-mediated conversion of T4 to T3 (Fig. 1C).
Growth plate chondrocytes only possess D3 enzyme activity
We next determined activities of the D1, D2 and D3 enzymes in
chondrocytes and growth plates (Table 1). D1, D2 and D3 activities
were undetectable in ATDC5 extracts at all stages of chondrogenesis in
4 independent experiments performed in duplicate. Medium analyzed
from ATDC5 cells incubated with 125I-labeled T3/T4 for 24 h also
revealed no evidence of deiodinase activity following HPLC analysis of
iodothyronine metabolites. Furthermore, treatment of ATDC5 cells
with dexamethasone, cAMP or TPA did not induce detectable activities
of D1, D2 or D3. Similarly, pooled growth plate extracts (n=6–12 per
age, 2 experiments in duplicate) from 3, 6 and 12 week old rats lacked
detectable D1, D2 or D3 activities. Primary chondrocytes from 6 and
12 week rats (n=6–12 animals per age, 2 experiments in duplicate)
also lacked D2 or D3 activity and chondrocytes from 3 week rats had
no detectable D2 activity. However, D3 enzyme activity was present in
chondrocytes from 3 week rats (n=12 animals per experiment, 2
experiments in duplicate) at levels ranging between 0.6–4.6 fmol/
min/mg in control cells and cells treated with dexamethasone, thyroid
hormones, dibutyryl cAMP and TPA. No signiﬁcant induction of D3
activity in response to TPA was evident. D3 activity in control extracts
from human fetal liver was 208 fmol/min/mg. Thus, growth plate
chondrocytes obtained from weaning rats possessed D3 activity but
lacked D1 and D2.
Osteoblasts express MCT8, D2 and D3 mRNAs throughout differentiation
The osteoblastic phenotype of MC3T3 cells in the absence and
presence of T3 was conﬁrmed in RT-PCR studies, which revealed
expression of the osteoblast marker genes Runx-2, Twist-2, osteocalcin,
alkaline phosphatase and type 1 collagen throughout the 28 day cell
culture period (Fig. 2A). T3 (1–100 nM) stimulated MC3T3-E1 cell
proliferation after 7 and 14 days, and increasedALPactivity after 7,14, 21
and 28 days (Fig. 2A, 100 nM response shown), demonstrating that T3
induces differentiation of MC3T3-E1 cells, which undergo a deﬁned
programme of osteoblastogenesis [48]. MCT8, D2 and D3 mRNAs were
expressed in primary mouse osteoblasts at all stages of differentiation
whereas D1 was undetectable (Fig. 2A). Similar ﬁndings were observed
inMC3T3-E1 cells (data not shown). To investigatewhether progression
of osteoblast differentiation was associated with altered expression of
MCT8 and deiodinases, we examined their expression by qRT-PCR in
human fetal osteoblastic SV-HFO cells, which differentiate over a period
of 21 days [20,25]. MCT8 was expressed throughout the culture period
with a cycle detection threshold (ΔCT) relative toGAPDHof between−10
to −11 cycles (ΔCT=CT GAPDH−CT MCT8). D2 and D3 mRNAs were
expressed at lower levels than MCT8 (ΔCT for D2=−15 to −13, ΔCT for
D3=−18 to −15), whereas expression of D1was at the limit of detection
(ΔCT=−23 to −25) (Fig. 2B). Thus, mouse and human osteoblasts
expressed D2 and D3 mRNAs throughout differentiation but did not
express a signiﬁcant amount of D1.
Osteoblasts possess D3 enzyme activity throughout differentiation and
D2 activity is present in mature osteoblasts
Extracts from differentiated MC3T3-E1 cells cultured for 28 days
did not possess D1, D2 or D3 enzyme activities (n=2–3 experiments in
duplicate) (Table 2). Furthermore, treatment of MC3T3-E1 cells with
dexamethasone, cAMP or TPA did not induce detectable activities ofD1, D2 or D3. Rat and mouse calvarial osteoblasts also undergo a
deﬁned programme of differentiation over 28 days [10,71]. Similar to
MC3T3-E1 cells, extracts from mature differentiated primary mouse
osteoblasts did not possess detectable D1 activity (n=3) but, by
contrast, expressed speciﬁc D2 (0.21 fmol/min/mg) and D3 (1.35 fmol/
min/mg) activities (Table 2). Activities of D1, D2 and D3 were also
determined in rat calvarial osteoblasts cultured for 11, 18, 20 and
27 days in the absence or presence of T3, T4 or dexamethasone (n=2
experiments in duplicate). Rat osteoblasts did not express detectable
D1 or D2 activities but possessed speciﬁc D3 activity in the absence
and presence of T3, T4 or dexamethasone at all time points (Table 2).
No alteration of D3 activity in response to these agents was evident.
Extracts from T3, T4 and dexamethasone-treated human SV-HFO cells
at days 1, 7, 14 and 21 did not possess D1 or D2 activities (Table 2), and
medium analyzed from cells incubated with 125I-labeled T3/T4 for
24 h prior to harvest at each time point also revealed no evidence of
D1 or D2 activities following HPLC analysis (n=2 in duplicate).
Treatment of SV-HFO cells with dexamethasone, cAMP or TPA did not
induce detectable D1 or D2 activity. D3 activity was also undetectable
in T3 and T4 treated SV-HFO cells at each time point, whereas low
levels of D3 activity were present in dexamethasone-treated cells at
days 14 and 21. Thus, primary osteoblasts possessed D3 enzyme
activity throughout differentiation and mature mouse osteoblasts also
expressed D2 activity.
Osteoclasts express varying levels of MCT8, D2 and D3 mRNAs during
differentiation
Culture of bone marrow from 6–8 week old rats or mice in the pre-
sence of RANKL for 9 days resulted in the generation of multinucleated
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TRAP (Fig. 3A) and cathepsin K (not shown). Differentiating osteoclasts
expressedMCT8,D2andD3mRNAsbut notD1mRNA.D2wasexpressed
throughout osteoclastogenesis, whereas D3 was absent during the ﬁrst
3 days of culture but expressed later at days 6 and 9. MCT8 expression
declined as osteoclastogenesis progressed (Fig. 3B). Thus, osteoclasts
expressed varying levels of D2 and D3mRNAs during differentiation but
did not express D1 mRNA.
Osteoclasts only possess D3 enzyme activity
Bone marrow cultures from 6–8 week old animals did not possess
detectable D1 or D2 activity in cell extracts, whereas D3 activity was
present in monocytic cells in the absence of RANKL and in osteoclasts
differentiated in the presence of RANKL (n=2 experiments in
triplicate, Table 3). RAW 264.7 cells undergo osteoclast differentiation
in response to RANKL over a period of 2–5 days [43]. Untreated and
RANKL treated cells after 3, 5 and 7 days in culture did not possess
detectable D1, D2 or D3 enzyme activity in cell extracts (n=2 ex-
periments in triplicate). Furthermore, medium from RAW 264.7 cells
incubatedwith 125I-labeled T3/T4 for 24 h prior to harvest at each time
point revealed no evidence of deiodinase activity following HPLC
analysis (Table 3). Thus, primary bone marrow osteoclasts expressed
D3 enzyme activity.
Discussion
There are incomplete and conﬂicting reports regarding the func-
tional expression of the iodothyronine deiodinase enzymes in skeletal
cells [1,17,24,30,42,49–51,69,76] and their physiological importance in
bone has not been exploredin vivo. Here, we show that D1 is not
expressed in skeletal cells, D2 activity is restricted to mature osteo-
blasts, and functional D3 enzyme is present in primary chondrocytes,
osteoblasts and osteoclasts.
In these studies, we show that D1 mRNA expression and enzyme
activity are undetectable in chondrocytes, osteoblasts and osteoclasts
from several sources, thus extending previous work in which D1
activity was not detected in osteoblastic cell lines [24,30,42]. These
ﬁndings are in agreement with general observations in inbred D1-
deﬁcient C3H/HeJ mice, which exhibit minor disturbances of the HPT
axis with normal T3 and TSH levels and modestly elevated T4 levels,
but have normal growth [11,67]. Furthermore, D1 knockout (D1−/−)
mice have a similar mild disturbance of the HPT axis and also display
normal growth with no obvious skeletal defect reported [66]. We
conclude, therefore, that D1 does not have a physiological role in the
skeleton.
To investigate D2 activity, we employed a highly speciﬁc and
sensitive D2 assay based on the measurement of radiolabeled T3
production as determined by HPLC [29]. This approach contrasts with
previous studies [50,51], which relied solely on sensitive detection of
125I− release that can result from non-speciﬁc substrate degradation
[30]. Our results unequivocally demonstrate the presence of speciﬁc
D2 activity in mature mouse calvarial osteoblasts, whereas speciﬁc D2
activity was undetectable in all other cells studied.
There are no previous data in osteoclasts but the lack of speciﬁc D2
activity in chondrocytes is apparently at odds with a previous study of
ATDC5 cells and growth plate organ cultures, which concluded that
deiodination of labeled rT3 in the presence of PTU was due to D2-like
activity [50]. This study, however, has been criticized as being non-
speciﬁc [30] because deiodination was only detected after prolonged
assay incubation and its kinetics, response to thyroid hormones and
proteasome inhibitionwere not assessed. Substantial PTU-insensitive,
non-saturable and non-speciﬁc outer ring deiodination has been
identiﬁed previously in bone cells [30] and this is likely be the source
of deiodination observed by Miura et al. [50]. Previous studies in
SaOS2 and NHOst osteoblastic cells have also reported substantiallevels (5–6 fmol/mg/min) of 5'-deiodination [51]. However, detection
of D2-like activity in osteoblastic cells, similar to studies in ATDC5 cells
and growth plate organ cultures [50], relied on the measurement of
125I− released from cell extracts [51]. It seems reasonable, therefore, to
conclude that levels of speciﬁc D2 activity contributing to the total 5'-
deiodination observed byMorimura in osteoblastic cells may be much
lower than 5-6 fmol/mg/min. Indeed, the 0.21 fmol/min/mg speciﬁc
D2 activity determined in mature primary murine osteoblasts in the
current studies is in close agreement with the levels of well-
characterized speciﬁc D2 activity (0.2–0.3 fmol/min/mg) observed
previously in mouse femur and bone marrow [30]. Nevertheless, in
contrast to the current study, Gouveia et al. [30] also demonstrated
speciﬁc D2 activity in differentiated conﬂuent MC3T3-E1 cells in the
presence of high Se concentrations. The discrepancy between these
ﬁndings and the current studies may reﬂect different cell culture
conditions or clonal differences between batches of MC3T3-E1 cells.
Even though speciﬁc D2 activity was only present in differentiated
mature murine osteoblasts, D2 mRNA was detected more widely in
growth plate chondrocytes (after 40 PCR cycles), primary rat
osteoblasts, MC3T3 and SV-HFO osteoblastic cells and osteoclasts.
Discordance between D2 mRNA expression and enzyme activity has
been documented before in skeletal cells. For example, Dentice et al.
showed speciﬁc expression of D2mRNA in hypertrophic chondrocytes
in the developing 8 day old chick, but did not detect enzyme activity
[23]. The D2 assay used in the current studies is highly speciﬁc and
sensitive [29], and enzyme activity was investigated in cell and tissue
extracts and in intact cells. Although it is possible that enzyme activity
was below the level of detection in all cells other than mature murine
osteoblasts, we conclude that if this was the case the speciﬁc D2
activity must be so low that it is reasonable to propose D2 does not
have such an important physiological role in bone as postulated
previously. An alternative possibility is that cells expressing D2 mRNA
encode a non-functional deiodinase. A more likely and attractive
explanation is that D2 activity is eliminated efﬁciently in bone cells
following degradation of the enzyme. The D2 protein is labile with
only a 20-min half-life because of post-translational regulation by
selective ubiquitination and targeted proteasomal degradation
[13,78]. Indeed, ubiquitin-mediated degradation of D2 is known to
regulate thyroid hormone activation in the embryonic growth plate
[23] and other tissues [13,26,63] thereby accounting for discordance
between D2 mRNA expression and enzyme activity.
Limited information is available regarding the effect of D2-
deﬁciency on the skeleton in vivo. D2−/−mice have pituitary resistance
to T4 with normal circulating T3 concentrations, but 1.4-fold elevated
T4 and 2-fold elevated TSH levels in adults. A transient period of 9%
reduced weight was evident between 4 and 7 weeks of age in males
but not females [65]. Recently, C3H/HeJ D2−/− compound mutant mice
with D1 deﬁciency and deletion of D2were shown tomaintain normal
growth and have normal T3 levels [21]. In agreement with the current
studies documenting an absence of D1 and D2 activities in growth
plate extracts and chondrocytes, ﬁndings in D1 and D2 mutant mice
indicate the supply of T3 to the skeleton during growth is not
compromised in the absence of either or both enzymes. Together with
ﬁndings in primary osteoclasts and RAW 264.7 cells, we conclude D2
does not have a physiological role in growth plate chondrocytes or
osteoclasts. Findings in differentiated murine primary osteoblasts
however suggest a possible role for D2 in mature osteoblast function.
To investigate further it will be necessary to examine the conse-
quences of D2 deletion in the adult skeleton, as osteoblast D2 may
regulate adult bone mineralization.
In contrast to the lack of D1 and restricted presence of D2 in bone,
D3 activity was more widespread. Speciﬁc D3 activity was present in
growth plate chondrocytes cultured fromweaning 3week old rats and
in all primary osteoblasts, primarymonocytes and primary osteoclasts
examined. By contrast, D3 activity was absent from ATDC5, MC3T3,
SV-HFO and RAW 264.7 cell lines, indicating that immortalized and
133A.J. Williams et al. / Bone 43 (2008) 126–134transformed cell lines do not adequately represent the D3-expressing
phenotype of primary bone cells. Interestingly, D3 activity was present
only in chondrocytes from 3 week old rats but not in cells from older
animals. The lack of D3 activity in cells from 6 and 12 week animals,
suggests that the enzyme may limit availability of thyroid hormones
in the growth plate until after weaning when T3-dependent linear
growth acceleration is initiated [7,32]. D3 activity was also expressed
in differentiating primary osteoblasts and osteoclasts and we
conclude, therefore, that that local T3 availability in bone cells is
controlled principally via D3-dependent regulation of thyroid hor-
mone catabolism.
Interestingly, D3−/−mice have neonatal thyrotoxicosis with a 4-fold
elevated T3 at post-natal day 5 due to diminished T3 clearance that is
followed by persistent central hypothyroidism from 2 weeks of age.
Severe growth retardation at weaning persists into adulthood and
remains at 1 year of age [33,34]. We showed previously that mice with
skeletal thyrotoxicosis resulting from mutation of TRβ display short
stature due to accelerated bone maturation in utero and premature
growth plate quiescence in the post-weaning period [4,5,57].
Furthermore, TRα mutant mice with skeletal hypothyroidism are
growth retarded in the post-weaning period because of delayed en-
dochondral ossiﬁcation [5,55,56]. The short stature observed in D3−/−
mice may therefore reﬂect accelerated bone maturation due to exces-
sive exposure to thyroid hormones prior to weaning because of absent
D3 expression in bone during this critical period. Additionally,
systemic hypothyroidism after 2 weeks of age will further delay
growth in the post-weaning period when systemic thyroid hormones
are essential, resulting in the severe growth phenotype observed in
D3−/− mice [33,34]. We hypothesize, therefore, that D3 plays an
essential role to limit thyroid hormone availability in the immature
skeleton and regulate bone development and linear growth. The role
of D3 in adult bone is difﬁcult to predict and analysis of the skeleton in
D3−/− mice is likely to be informative.
In conclusion, these studies suggest that thyroid hormone access
and availability to bone is unlikely to be a limiting factor that regulates
thyroid hormone responsiveness in the developing skeleton. Indeed,
we show that MCT8 mRNA is expressed in all bone cell lineages.
Rather, the developing skeleton may be unusual as it appears that
control of thyroid hormone availability is determined by D3-mediated
catabolism. This contrasts with other tissues such as cochlea and brain
in which hormone availability is determined mainly by D2 [31,54],
although D3 also plays a role in fetal brain by regulating the spatial
availability of thyroid hormones [38]. In mature osteoblasts hormone
availability is likely to be tightly regulated at the level of both T3
production and catabolism by the relative activities of D2 and D3. The
current ﬁndings provide new insight into our understanding of
thyroid hormone action in skeletal cells but our understanding of the
physiological role of the deiodinase enzymes in bone in vivo will
require detailed analysis of deiodinase mutant mice.
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